Chronic airways infection and inflammation is the greatest source of morbidity and mortality
in cystic fibrosis (CF) patients. Many organisms can be found in the lower respiratory tract of …

High rates of colonization and the challenge of managing Pseudomonas aeruginosa
infections in patients with cystic fibrosis (CF) have necessitated a search for safe and …

Repeated bouts of acute and chronic lung infections are responsible for progressive
pulmonary function decline in individuals with cystic fibrosis (CF), ultimately leading to …

There are strong data supporting using the use of aerosolized antibiotics for the treatment of
Gram-negative infections in patients with cystic fibrosis (CF). The regular use of aerosol …

Background Direct aerosol delivery of aminoglycosides such as tobramycin to the lower
airways of patients with cystic fibrosis may control infection with Pseudomonas aeruginosa …

Chronic airway infection with Pseudomonas aeruginosa is a major cause of increased
morbidity and mortality in patients with cystic fibrosis (CF). The development and …

Early studies of the use of antibiotics in patients with cystic fibrosis suggested that they
would be of benefit in preventing or reducing infection by Pseudomonas aeruginosa. In …

Nebulization is a useful administration route in cystic fibrosis (CF) as it delivers antibiotics
directly to the endobronchial site of infection and is associated with decreased toxicity …

Pseudomonas aeruginosa (PA), which colonizes the airways of approximately 90% of
patients with cystic fibrosis (CF) at some point during their lives, is an important contributor to …

Lung disease in cystic fibrosis (CF) is typified by the development of chronic airways
infection culminating in bronchiectasis and progression to end-stage respiratory disease …